Tests XmAb541 for safety in people with advanced solid tumors
Tests the new drug XmAb541 for safety and dosing in advanced ovarian and endometrial cancers.
Plain-language title generated from the registry record
Registry title: Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Key facts
- Where
- Pierre-Bénite, FranceSee the site
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced ovarian, fallopian tube, peritoneal, endometrial or germ cell tumors that carry CLDN6 and have come back, spread or stopped responding to treatment.
- Age
- 18 years or older. In the US only, people with germ cell tumors can join from age 15.
- Sex
- All sexes can join.
- Disease stage
- Locally advanced, recurrent or metastatic ovarian, fallopian tube or peritoneal cancer, or endometrial (uterine) cancer. Germ cell tumors that did not respond to earlier treatment are also accepted.
- Earlier treatment
- Germ cell tumors must be resistant to previous treatment.
- Biomarker or test result
- The tumor must be CLDN6+ (CLDN6 positive).
Main reasons for not taking part
- Untreated brain metastases (treated ones can join if stable on scans)
- Active known or suspected autoimmune disease
- Needing steroids or other immune-suppressing medicines within 14 days before the first dose
- Clinically significant heart, lung or digestive disease
- Active hepatitis B or hepatitis C
Read by machine on 12 November 2026.
Where in France
- Centre Hospitalier Lyon-SudPierre-Bénite, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Xencor, Inc.
- Trial code
- NCT06276491
- Record updated
- 9 October 2026
- Original description
The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.Read full original descriptionShow less
A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 in Advanced Solid Tumors
The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.
Inclusion: Age ≥ 18 years. For US only: subjects with GCTs, age ≥15 years; CLDN6+ tumor; Histological or cytological documentation of locally advanced, recurrent, or metastatic ovarian, fallopian tube, or peritoneal cancer, adenocarcinoma of the endometrium (endometrial cancer, uterine cancer, or carcinoma of the uterine corpus), GCT resistant to previous treatment; Adequate Eastern Cooperative Oncology Group performance status; Life expectancy ≥ 3 months; Adequate liver, kidney, and bone marrow function.
Exclusion: Have any condition requiring systemic treatment with corticosteroids, prednisone equivalents, or other immunosuppressive medications within 14 days prior to first dose of study drug; Active known or suspected autoimmune disease; Clinically significant cardiovascular, pulmonary or gastrointestinal disease; Active hepatitis B or hepatitis C; Participants with untreated brain metastases are excluded. Participants with treated brain metastases may participate, provided they are radiologically stable.